Reuters logo
BRIEF-BioLineRX says topline results for phase 2 BL-8040 study expected by 2017-end
2017年3月20日 / 中午12点14分 / 8 个月前

BRIEF-BioLineRX says topline results for phase 2 BL-8040 study expected by 2017-end

March 20 (Reuters) - BioLineRx Ltd:

* BioLineRx provides update on phase 2 open-label study for BL-8040 as novel stem cell mobilization treatment

* Top-Line results expected by end of 2017

* BL-8040 treatment was safe and well tolerated

* All recipients transplanted so far have experienced a successful neutrophil engraftment Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below